Spring Bank Pharmaceuticals (NASDAQ:SBPH) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.
SBPH has been the topic of several other reports. B. Riley assumed coverage on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They issued a “buy” rating and a $30.00 price objective on the stock. Chardan Capital reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Sunday, September 17th. Dawson James reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. Finally, Cantor Fitzgerald set a $29.00 price objective on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $27.25.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) opened at $13.98 on Friday. Spring Bank Pharmaceuticals has a 12 month low of $6.31 and a 12 month high of $18.93.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
What are top analysts saying about Spring Bank Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spring Bank Pharmaceuticals Inc. and related companies.